MiR-630 Overexpression in Hepatocellular Carcinoma Tissues is Positively Correlated with Alpha-fetoprotein
Overview
Pathology
Authors
Affiliations
Background: MicroRNA-630 (miR-630) has been shown to be involved in various human malignancies. However, its role in hepatocellular carcinoma (HCC) remains unknown.
Material And Methods: TaqMan qRT-PCR assay was performed to detect the expression of miR-630 in 42 pairs of HCC tissues and corresponding noncancerous hepatocellular tissues, and its correlations with clinicopathologic features and serum alpha-fetoprotein (AFP) level of patients were analyzed.
Results: The present study found that miR-630 expression was significantly increased in HCC tissues and cells compared with their normal counterparts. miR-630 expression level did not significantly chang at stage I but was markedly increased at advanced TNM stage (stage II~III). In addition, the increased expression of miR-630 in tissues of HCC appeared in patients who exhibited elevated serum levels of AFP (>25 ng/ml), but not in those with normal AFP levels (≤25 ng/ml). The miR-630 expression in carcinoma tissues revealed a positive correlation with the levels of serum alpha-fetoprotein (AFP; R2=0.768).
Conclusions: These results suggest that miR-630 is associated with tumor progression of hepatocellular carcinoma and may be a potential prognosis indicator.
You G, Cheng A, Shen E, Fan K, Huang Y, Huang Y Cells. 2023; 12(24).
PMID: 38132173 PMC: 10741482. DOI: 10.3390/cells12242853.
Fatima S, Nasim M, Malik A, Rehman S, Waris S, Rauf M PLoS One. 2023; 18(8):e0289082.
PMID: 37540697 PMC: 10403070. DOI: 10.1371/journal.pone.0289082.
The importance of miRNA-630 in human diseases with an especial focus on cancers.
Kadkhoda S, Ghafouri-Fard S Cancer Cell Int. 2022; 22(1):105.
PMID: 35248081 PMC: 8897855. DOI: 10.1186/s12935-022-02531-z.
FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis.
Kalathil D, John S, Nair A Front Oncol. 2021; 10:626836.
PMID: 33680951 PMC: 7927600. DOI: 10.3389/fonc.2020.626836.
Fei X, Zhang P, Pan Y, Liu Y Yonsei Med J. 2020; 61(6):460-470.
PMID: 32469170 PMC: 7256008. DOI: 10.3349/ymj.2020.61.6.460.